Header cover image

Taiwanese (TAIEX) Biotech Industry Analysis

UpdatedJun 30, 2022
DataAggregated Company Financials
Companies48
  • 7D5.9%
  • 3M7.8%
  • 1Y28.6%
  • YTD17.8%

Over the last 7 days, the Biotech industry has risen 1.6%, driven by gains from PharmaEssentia of 11%. In the last 12 months, the industry was up 24%. Looking forward, earnings are forecast to grow by 150% annually.

Industry Valuation and Performance

Has the Taiwanese Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPE
Thu, 30 Jun 2022NT$550.2bNT$22.5b-NT$5,642,821,000.0031.1x
Sat, 28 May 2022NT$494.7bNT$22.5b-NT$5,642,821,000.0031.8x
Mon, 25 Apr 2022NT$541.4bNT$21.5b-NT$5,722,660,000.0034.7x
Wed, 23 Mar 2022NT$513.4bNT$19.4b-NT$4,874,140,000.0028.3x
Fri, 18 Feb 2022NT$466.6bNT$17.9b-NT$5,564,340,000.0025.1x
Sun, 16 Jan 2022NT$427.1bNT$17.9b-NT$5,532,702,000.0025x
Tue, 14 Dec 2021NT$466.7bNT$17.9b-NT$5,579,296,000.0024.4x
Thu, 11 Nov 2021NT$353.3bNT$15.4b-NT$7,624,179,000.0020.9x
Sat, 09 Oct 2021NT$343.8bNT$15.4b-NT$7,624,179,000.0019.9x
Mon, 06 Sep 2021NT$379.0bNT$15.4b-NT$7,624,179,000.0022.7x
Wed, 04 Aug 2021NT$400.1bNT$15.4b-NT$7,624,179,000.0021.5x
Sat, 08 May 2021NT$403.0bNT$13.7b-NT$8,453,670,500.0026.8x
Tue, 09 Feb 2021NT$272.0bNT$13.4b-NT$8,436,837,000.0023.8x
Mon, 02 Nov 2020NT$275.1bNT$11.8b-NT$10,319,873,500.0078.3x
Thu, 06 Aug 2020NT$290.5bNT$11.2b-NT$10,631,308,000.0051.2x
Sun, 10 May 2020NT$194.0bNT$10.8b-NT$10,916,068,500.0061.2x
Sat, 01 Feb 2020NT$202.7bNT$10.4b-NT$10,971,126,000.0037.4x
Tue, 05 Nov 2019NT$213.1bNT$9.7b-NT$11,320,634,500.0033.1x
Fri, 09 Aug 2019NT$233.8bNT$9.3b-NT$11,458,869,000.0032.6x
Median PE Ratio

31x


Total Market Cap: NT$234.1bTotal Earnings: -NT$11,458,869,000.00Total Revenue: NT$9.3bTotal Market Cap vs Earnings and Revenue0%0%0%
Taiwanese Biotech Industry Median PE3Y Average 37.6x202020212022
Current Industry PE
  • Investors are relatively neutral on the industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 23.9x.
Past Earnings Growth
  • The earnings for companies in the Biotechnology industry have improved over the last three years.
  • Revenues for these companies have grown 35% per year.
  • This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.

Industry Comparison

How does Taiwanese Biotech compare with similar industries?

TW Market-0.49%
Healthcare3.98%
Biotech5.86%
Biotech5.86%
Industry PEThere is insufficient data on the sub-industries of this industry.
Forecasted GrowthThere is insufficient data on the sub-industries of this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
6446 PharmaEssentiaNT$542.0010.8%
+NT$15.1b
524.4%PS189.9x
6550 Polaris GroupNT$119.0012.8%
+NT$9.7b
63.2%PS5688.3x
4142 AdimmuneNT$40.8510.9%
+NT$1.7b
-23.8%PE301.2x
6617 Gongwin Biopharm HoldingsNT$284.505.6%
+NT$1.6b
29.9%PS27382.1x
4726 Mycenax BiotechNT$43.0018.1%
+NT$1.0b
0.4%PS9.4x
Simply Wall St™
Simply Wall Street Pty Ltd
17-21 Bellevue Street, Surry Hills, Sydney
Download on the App StoreGet it on Google Play
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

4142

NT$40.85

Adimmune

7D

10.9%

1Y

-23.8%